Prognostic significance of K-ras mutations in pancreatic cancer: a meta-analysis

Table 3 The hazard ratios for overall survival comparing K-ras mutations with the wild-type in the included studies

The author	Year	K-ras (mutant/wild)	HR (95 % CI)	P value	Sites
Allison, D.C. [16]	1998	64/12	0.70 (0.35–1.43)	0.330	NR
Boeck, S [17]	2013	121/52	1.68 (1.17–2.41)	0.005	12, 13
Kim, S.T [18]	2011	71/65	1.68 (1.18–2.39)	0.001	12, 13
Ogur, T [19]	2014	214/28	1.76 (1.03–3.01)	0.040	12
Schultz, N.A. [6]	2012	136/34	1.15 (0.75–1.77)	0.510	12, 13, 61
Shin, S.H. [20]	2013	126/108	1.63 (1.13–2.34)	0.001	12, 13
Sinn, B.V. [7]	2014	105/48	1.68 (1.07–2.62)	0.023	12, 13, 61
Franko, J [21]	2008	31/19	3.28 (1.09–9.90)	0.035	12, 13, 1
da Cunha Santos, G [22]	2010	92/25	0.68 (0.33–12.42)	0.300	12, 13
Fensterer, H [5]	2013	45/21	1.28 (0.62–2.64)	0.180	12, 13
lkeda, N [23]	2001	33/15	1.83 (0.87–3.88)	0.317	12
Kwon, M.J. [24]	2011	34/38	1.65 (0.90–3.01)	0.159	12, 13, 1
Lee, J [25]	2007	33/33	1.51 (1.01–2.66)	0.030	12
Oh, D.Y. [26]	2012	19/21	2.03 (0.43–9.61)	0.158	12, 13
Salek, C [27]	2009	36/17	0.83 (0.38–1.83)	0.636	12, 13
Kinugasa, H [28]	2015	47/28	1.59 (0.88–3.07)	0.124	12, 13, 61
Talar-Wojnarowska, R [29]	2005	20/6	0.87 (0.23–3.29)	0.580	12

NR not reported, Sites sites of K-ras mutations involved, such as codons 12, 13, and 61

ISSN: 1477-7819